- Home
- ANL vs NRXP Comparison
ANL vs NRXP Comparison
Compare ANL & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANL | NRXP |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 73.7M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANL | NRXP |
|---|---|---|
| Price | $1.25 | $2.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $30.50 |
| AVG Volume (30 Days) | 10.1K | ★ 447.9K |
| Earning Date | 11-07-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $242,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $643.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $1.15 |
| 52 Week High | $2.99 | $6.01 |
Technical Indicators
Market Signals| Indicator | ANL | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 31.42 | 45.85 |
| Support Level | $1.20 | $2.22 |
| Resistance Level | $1.59 | $2.51 |
| Average True Range (ATR) | 0.14 | 0.19 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 2.56 | 72.22 |
Price Performance
Historical ComparisonAbout ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.